NASDAQ:CDXSCodexis Stock Price, Forecast & News

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 19.3% and is now trading at $12.07. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Codexis.

Codexis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The biotechnology company earned $14.67 million during the quarter, compared to analysts' expectations of $12.53 million. Codexis had a negative net margin of 21.40% and a negative return on equity of 14.24%. View Codexis' earnings history.

2 equities research analysts have issued 1 year price objectives for Codexis' stock. Their forecasts range from $21.00 to $21.00. On average, they expect Codexis' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 74.0% from the stock's current price. View analysts' price targets for Codexis.

Headlines about CDXS stock have trended neutral this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Codexis earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near term. View the latest news about Codexis.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), Crispr Therapeutics (CRSP), Micron Technology (MU), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX) and Enphase Energy (ENPH).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $12.07.

Codexis has a market capitalization of $712.37 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]